U.S. market Closed. Opens in 1 day 12 hours 7 minutes

VRAX | Virax Biolabs Group Limited Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2024-03-312023-03-312022-03-312021-03-312020-03-31
Revenue156.42K8.56KN/A123.82K99.88K
Cost of Revenue105.83K9.93KN/A133.25K54.13K
Gross Profit50.59K-1.36KN/A-9.43K45.75K
Operating Expenses6.55M5.73M1.73M635.10K696.99K
Selling, General & Admin4.59M5.33M1.30M514.88K609.99K
Research & Development1.56M397.11K433.74K120.22K87.00K
Other Operating Expenses390.36K290.47KN/A266.002.47K
Operating Income-6.50M-5.73M-1.73M-644.54K-651.24K
Other Expenses / Income-242.65K275.00K-16.19K-28.38K-88.22K
Before Tax Income-6.74M-5.46M-1.75M-672.91K-739.46K
Income Tax ExpensesN/A-271.00-1.77M-666.47K61.67K
Net Income-6.73M-5.46M-1.71M-650.98K-801.13K
Interest Expenses26.88K15.47K15.44K28.64K90.69K
Basic Shares Outstanding2.01M1.06M1.14M1.14M1.14M
Diluted Shares Outstanding2.01M1.06M1.14M1.14M1.14M
EBITDA-6.61M-5.44M-750.00N/A-648.77K
EBITDA Margin-4,225.28%-63,570.74%0.00%0.00%-649.58%
EBIT-6.71M-5.44M-3.47M-1.29M-648.77K
EBIT Margin-4,287.62%-63,570.81%0.00%-1,040.87%-649.58%
Financial Year End2024-03-312023-03-312022-03-312021-03-312020-03-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙